• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Vir Biotechnology (VIR) Is Up 5.1% After Astellas Cancer Deal And Equity Raise News

    Simply Wall St·03/08/2026 15:13:09
    Listen to the news
    • In late February 2026, Vir Biotechnology announced a global collaboration with Astellas Pharma around its investigational prostate cancer therapy VIR-5500, alongside positive early Phase 1 data, a US$150,000,002 follow-on equity raise, new shelf registration and its 2025 earnings results.
    • Together, the Astellas partnership economics, encouraging early VIR-5500 data and fresh equity capital appear to materially reshape Vir Biotechnology’s funding mix, oncology profile and long-term development priorities.
    • We’ll now examine how the Astellas collaboration around VIR-5500 could influence Vir Biotechnology’s existing investment narrative and risk-reward balance.

    AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Vir Biotechnology Investment Narrative Recap

    To own Vir Biotechnology, you have to believe its transition from an infectious disease story to a higher-risk oncology and hepatitis delta platform can justify ongoing losses and dilution. The Astellas deal and positive early VIR-5500 data sharpen VIR-5500 as the key near term catalyst, while the biggest current risk remains execution across multiple early stage programs with no approved products yet, despite the bolstered balance sheet and reduced funding pressure.

    Among the recent announcements, the US$335 million Astellas collaboration around VIR-5500 stands out as most relevant. It shifts a large share of development costs to Astellas, brings in premium priced equity, and ties future upside to milestones and royalties. This may influence how investors weigh VIR-5500 versus hepatitis programs as potential value drivers, and how they assess the trade off between dilution, cash burn and clinical execution risk.

    Yet while the new funding and partnership look reassuring, investors still need to be aware of...

    Read the full narrative on Vir Biotechnology (it's free!)

    Vir Biotechnology's narrative projects $64.7 million revenue and $10.3 million earnings by 2028. This assumes revenues will decrease by 4.5% per year and that earnings will improve by about $532 million from -$522.0 million today.

    Uncover how Vir Biotechnology's forecasts yield a $20.78 fair value, a 118% upside to its current price.

    Exploring Other Perspectives

    VIR 1-Year Stock Price Chart
    VIR 1-Year Stock Price Chart

    Some analysts had already built in very optimistic scenarios, with revenue growth of about 176% a year and possible earnings of roughly US$57.8 million by 2029, so this new Astellas deal and VIR 5500 data could either reinforce that upbeat view or highlight how contingent it is on the PRO XTEN platform delivering as hoped.

    Explore 2 other fair value estimates on Vir Biotechnology - why the stock might be worth just $12.00!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Seeking Other Investments?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.